Echosens Observes October 2018 Liver Cancer Awareness Month: Know Your Risk for Nonalcoholic Fatty Liver Disease – A Looming National Epidemic

Supports greater awareness of high prevalence, disease risk factors,
importance of early detection and impact on healthcare costs

WALTHAM, Mass.–(BUSINESS WIRE)–In support of Liver Cancer Awareness Month alongside the American
Liver Foundation
, Echosens
calls for increased awareness of non-alcoholic fatty liver disease
(NAFLD) and its more severe form called non-alcoholic steatohepatitis
(NASH), which is projected to become the leading cause for liver
transplants by the year 2030. The good news is that NAFLD is reversible
if caught in the early stages and accompanied by lifestyle changes. With
estimates that about 20 percent of people with NAFLD have NASH, early
detection can help
to prevent
more serious conditions such as cirrhosis or scarring of
the liver, and hepatocellular carcinoma (HCC), or liver cancer.

Laurent Sandrin, founder of Echosens, an innovative high-technology
company offering the FibroScan family of products, explains, “NAFLD is
an asymptomatic disease and one of the most common causes of liver
disease in the US, affecting the livers of more than 100
million Americans
– over 30 percent of the US population.”

NAFLD is the accumulation of significant amounts of excess fat in the
liver, which is not caused by alcohol. It is more common among people
age 40-60 who are overweight, diabetic, or have high cholesterol or
triglycerides, with greater prevalence among women.

“NAFLD is one of the most common causes of liver disease in the U.S.,
yet a lack of awareness regarding symptoms and risk factors continues to
fuel this silent epidemic,” says Tom F. Nealon, president and CEO of the
American Liver Foundation. “The good news is that NAFLD is oftentimes
reversible with the implementation of a healthy lifestyle. We have the
ability to stem this deadly disease though increased awareness and early
detection. So please, speak with your physician today to determine your
risk. Catching NAFLD in its earliest stages can stem the progression of
liver disease and save thousands of patients from developing NASH.”

An interim look at an ongoing study of 10,000 patients with no history
of liver disease was conducted in community-based endoscopy centers by
the Florida
Research Institute (FRI)
, a global leader in disease research. Among
the key findings, only 43 percent of patients evaluated had what is
considered normal livers, while the remainder of patients had some form
of liver abnormality, ranging from elevated liver fat to liver fibrosis.
The study used FibroScan, the non-invasive backbone for cost effectively
diagnosing and managing liver disease at point of care, to measure fat
and stiffness levels in the liver.

Guy Neff, M.D., MBA, director of the FRI and principal investigator of
the study, reports, “This analysis of the first 367 patients suggests a
significant rate of undiagnosed steatohepatitis liver disease in the
population studied. These results underscore the importance of
identifying asymptomatic patients who may be at risk for advancing
disease for earlier intervention. This high prevalence of disease, a
dramatic rise from our observations in the last decade, are indicative
of the critical need for ongoing assessment.”

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology
company offering a full range of products and services supporting
physicians in their assessment and management of patients with chronic
liver diseases. FibroScan® is supported by over 2,000 peer reviewed
publications. http://www2.echosens.com/AboutFibroScan

About the American Liver Foundation

Founded in 1976, the American Liver Foundation (ALF) is the nation’s
largest patient advocacy organization for people with liver disease. ALF
reaches more than 2 million individuals each year with health
information, education and support services via its national office, 16
U.S. divisions and an active online presence. Recognized as a trusted
voice for liver disease patients, ALF also operates a national toll-free
helpline (800-GO-LIVER), educates patients, policymakers and the public,
and provides grants to early-career researchers to help find a cure for
all liver diseases. ALF is celebrating more than 40 years of turning
patients into survivors. For more information about ALF, please visit www.liverfoundation.org.


For Echosens
Mary Spardel, 201-641-1911 x22


I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.